[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Badr University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":347},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,68,92,117,146,171,198,225,252,275,301,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641143","inflammatory-cytokines-and-oxidative-stress-biomarkers-in-diabetic-chronic-kidney-disease-patients-100641143",false,"NCT07657286","Inflammatory Cytokines and Oxidative Stress Biomarkers in Diabetic Chronic Kidney Disease Patients","Inflammatory Cytokines and Oxidative Stress Biomarkers Response to Life Style Modification in Diabetic Chronic Kidney Disease Patients","intervention","Inclusion Criteria:\n\n* sedentary lifestyle for at least three months prior to enrollment\n* body mass index (BMI) of 30-35 kg\u002Fm².\n\nExclusion Criteria:\n\n* using tobacco\n* heart failure\n* coronary arteries\n* severe heart valve problems\n* pregnant\n* liver inflammation\n* kidney transplant\n* physical injuries restricting them from exercising\n* utilization of anti-inflammatory medications","ALL","36 Years","58 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This research intends to analyze how a 12-week adjustment in lifestyle influences inflammatory cytokines and oxidative stress indicators in overweight individuals diagnosed with type 2 diabetes and moderate CKD",[28,29],"Chronic Kidney Disease","Diabetes",[31],"Diabetes; Weight Reduction; Oxidative Stress; Cytokines; Obesity.","RECRUITING","2026-06-14",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":36},"2026-06-07",{"date":40,"type":22},"2026-09-07",{"name":42,"class":43},"Badr University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100635268","impact-of-pharmacist-led-intervention-on-adult-oncology-outpatients-100635268","NCT07550478","Impact of Pharmacist-Led Intervention on Adult Oncology Outpatients","Impact of Pharmacist-Led Medication Reconciliation, Counseling and Follow-Up on Medication Adherence, Medication Errors and Medication-related Hospitalization in Adult Oncology Outpatients","Inclusion Criteria:\n\n* • Adult medical oncology outpatient at NCI, Cairo University with different diagnoses.\n\n  * Receiving ≥5 medication\n\nExclusion criteria:\n\n* Cognitive impairment,\n* Palliative care\n* Language barriers","18 Years","65 Years",{"count":55,"type":22},100,[25],"Background and Rationale: Cancer patients receiving outpatient therapy often manage complex medication regimens that include anticancer agents, supportive care medications, and treatments for chronic comorbidities. This polypharmacy greatly increases the risk of medication discrepancies, potential drug-drug interactions, and unintentional errors. Moreover, because most oncology care is delivered in outpatient settings, patients are primarily responsible for self-administering their medications, making adherence a key determinant of treatment success and patient safety (Lindenmeyer et al., 2022; Alshehri et al., 2024). Medication errors and poor adherence among oncology patients are widely recognized global concerns. Research indicates that nearly half of cancer patients experience at least one medication discrepancy during transitions of care, and nonadherence to oral anticancer therapies can exceed 40%. Such issues can result in reduced treatment efficacy, increased toxicity, avoidable hospitalizations, higher healthcare costs, and poorer quality of life (Weingart et al., 2018; Wu et al., 2020; Patel et al., 2021). Pharmacists, as essential members of the multidisciplinary oncology team, are uniquely positioned to address these medication-related challenges. Their pharmacotherapy expertise and patient-education roles enable them to detect discrepancies, optimize medication use, and enhance patient understanding of treatment regimens. Evidence from various healthcare settings shows that pharmacist-led interventions such as medication reconciliation, individualized counseling, and structured follow-up can improve medication safety and adherence (de Clercq et al., 2021; Boeni et al., 2022). Despite strong evidence supporting each of these interventions individually, few studies have examined the combined effect of pharmacist-led reconciliation, counseling, and follow-up in outpatient oncology practice. Adult cancer patients face additional challenges, including complex dosing schedules, emotional distress, and financial burdens, all of which can impair medication adherence. An integrated pharmacist led program may create a continuous safety net that detects medication discrepancies early, reinforces correct use, and sustains adherence throughout treatment (Gellad et al., 2022; ISPOR Report, 2023). Therefore, this study aims to evaluate the impact of a comprehensive pharmacist-led program encompassing medication reconciliation, individualized counseling, and systematic follow-up on enhancing medication adherence and reducing medication errors among adult outpatient cancer patients. Demonstrating the effectiveness of this integrated care model may provide strong evidence to support the routine inclusion of pharmacists in outpatient oncology services to improve patient outcomes and medication safety (Alshehri et al., 2024; Boeni et al., 2022).\n\nStudy Hypothesis: Adult oncology outpatients are frequently prescribed complex medication regimens upon leaving the hospital. Therefore, this study aims to evaluate whether a comprehensive pharmacist-led outpatient program improves medication adherence and reduces medication errors among this population.",[59],"Cancer","NOT_YET_RECRUITING","2026-04-20",{"date":63,"type":36},"2026-04-24",{"date":61,"type":22},{"date":66,"type":22},"2026-07-20",{"name":42,"class":43},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":15,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":44},"100635394","low-intensity-laser-therapy-on-immune-system-response-among-children-with-pneumonia-100635394","NCT07552116","Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia","Impact of Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia","Inclusion Criteria:\n\n* Dawn Syndrome children with pneumonia\n* Mean age of 3.73±1.82 year\n* Children were in the first attack of bronchopneumonia.\n\nExclusion Criteria:\n\n* Other chest disease","3 Years","5 Years",{"count":78,"type":22},40,[25],"Objective: The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, were included into ; group (A) received low intensity laser therapy, inspiratory muscle training in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.",[82],"Pneumonia",[84],"Laser, Immune, Pneumonia, Dawn syndrome",{"date":86,"type":36},"2026-04-27",{"date":88,"type":36},"2026-04-06",{"date":90,"type":22},"2026-05-30",{"name":42,"class":43},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100623677","phase-3-effects-of-lower-body-positive-pressure-therapy-versus-alpha-lipoic-acid-and-omega-3-fatty-acids-on-knee-osteoarthritis-100623677","NCT07399743","Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis","Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Pain, Function, and Inflammation in Overweight Women With Knee Osteoarthritis: A Randomized Controlled Clinical Trial","* Inclusion criteria\n\n  1. Female participants aged between 20-45 years.\n  2. Their BMI ranged between 20-25 kg\u002Fm².\n  3. All had radiographic confirmation of mild to moderate knee osteoarthritis.\n  4. Medical history recorded with no major prior injuries or surgeries affecting outcomes.\n  5. Participants reported knee pain, functional limitation, and activity-related symptoms.\n  6. Radiographic grading confirmed as Kellgren-Lawrence grade II or III.\n\nExclusion criteria:\n\n1. No recent traumatic hip, knee, or ankle surgery within the past 6 months.\n2. No severe knee OA (Kellgren-Lawrence grade 0 or 4).\n3. No history of rheumatoid arthritis, chronic reactive arthritis, or psoriatic arthritis.\n4. Free from conditions that limit safe study participation or adherence to protocol.\n5. No neurological impairments affecting lower limb function.\n6. No contraindications to exercise or physiotherapy (e.g., severe cardiovascular, respiratory, or metabolic conditions).\n7. Not pregnant or planning pregnancy during the study.\n8. Not involved in other clinical trials or conflicting interventions (e.g., intra-articular injections, surgery, or rehab programs).","FEMALE","20 Years","45 Years",{"count":103,"type":22},160,[105],"PHASE3","Here is a \\*\\*concise, clear summary (\\~250 words \u002F well under 5000 characters)\\*\\* while preserving the key scientific points:\n\n\\---\n\nKnee osteoarthritis (KOA) is highly prevalent among overweight women, affecting more than 30% of those with BMI ≥25 kg\u002Fm². Excess body weight increases knee joint loading by 4-6 times per additional kilogram, accelerating cartilage degeneration, subchondral bone changes, and synovial inflammation. These alterations result in chronic pain, stiffness, functional limitation, and reduced quality of life, with obesity-related metabolic inflammation further worsening disease progression.\n\nStandard physical therapy (PT) remains first-line treatment, yet provides only modest benefits, achieving approximately 15-20% WOMAC improvement at 12 weeks, while up to half of overweight patients continue to experience significant symptoms. Lower body positive pressure therapy (LBPP) via antigravity treadmill offers a biomechanical enhancement by unloading 40-80% of body weight, enabling pain-free gait training and reducing joint impact forces by up to 80%. Studies report 30-40% WOMAC improvement and better walking capacity compared with conventional PT.\n\nNevertheless, mechanical interventions alone do not address the inflammatory and oxidative mechanisms driving KOA. Alpha-lipoic acid (600 mg\u002Fday) and omega-3 fatty acids (1.5-2 g\u002Fday) provide targeted biochemical modulation, reducing pro-inflammatory cytokines, oxidative stress, and cartilage-degrading enzymes, with reported 25-35% functional improvement in clinical trials.\n\nDespite the promise of both approaches, no randomized trial has directly compared adding LBPP versus combined ALA and omega-3 supplementation to standard PT in overweight women with KOA. This study aims to fill this gap by evaluating the relative effectiveness of biomechanical versus biochemical adjuncts to optimize management of KOA in this high-risk population.",[108],"Knee Osteoarthritis","2026-02-03",{"date":111,"type":36},"2026-02-10",{"date":113,"type":22},"2026-02-15",{"date":115,"type":22},"2026-07-01",{"name":42,"class":43},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":99,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":44},"100623381","phase-3-effect-of-metformin-iontophoresis-on-knee-osteoarthritis-in-postmenopausal-women-100623381","NCT07395895","Effect of Metformin Iontophoresis on Knee Osteoarthritis in Postmenopausal Women","Effect of Metformin Iontophoresis Combined With Physical Therapy Rehabilitation on Knee Osteoarthritis in Postmenopausal Women: A Randomized Double-Blind Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* • Postmenopausal women aged 50-70 years.\n\n  * Clinical and radiographic diagnosis of knee osteoarthritis according to the American College of Rheumatology criteria.\n  * Radiographic severity classified as Kellgren-Lawrence grade II or III.\n  * Chronic knee pain for a duration of at least 3 months.\n  * Pain intensity ≥4 on the Visual Analog Scale.\n  * Ability to ambulate independently with or without assistive devices.\n  * Ability to understand and follow instructions.\n  * Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* • Severe knee osteoarthritis (Kellgren-Lawrence grade IV).\n\n  * History of knee surgery or intra-articular injections within the previous 6 months.\n  * Presence of inflammatory rheumatic diseases such as rheumatoid arthritis or gout.\n  * Neurological disorders affecting lower limb function.\n  * Uncontrolled metabolic, cardiovascular, or systemic diseases.\n  * Current or recent use of metformin or other antidiabetic medications.\n  * Skin lesions, infections, or hypersensitivity at the iontophoresis site.\n  * Contraindications to electrotherapy such as pacemakers or implanted electronic devices.\n  * Body mass index ≥35 kg\u002Fm².\n  * Participation in another clinical trial within the last 3 months.","50 Years","70 Years",{"count":127,"type":22},68,[105],"This study is designed as a randomized, double-blind, placebo-controlled clinical trial with two parallel groups. All participants will receive a standardized physical therapy rehabilitation program. Participants will be randomly allocated into either a study group receiving metformin iontophoresis or a control group receiving placebo iontophoresis. Both participants and outcome assessors will be blinded to group allocation.",[131],"Osteoarthritis in Postmenopausal Women",[133,134,135,136,137],"Metformin gel","Iontophoresis","Physical Therapy Rehabilitation","Osteoarthritis","Postmenopausal Women","2026-02-01",{"date":140,"type":36},"2026-02-09",{"date":142,"type":22},"2026-03-01",{"date":144,"type":22},"2026-05-01",{"name":42,"class":43},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100621128","immune-profile-and-respiratory-parameters-in-down-syndrome-children-with-acute-pneumonia-pre-intervention-analysis-100621128","NCT07366593","Immune Profile and Respiratory Parameters in Down Syndrome Children With Acute Pneumonia: Pre-Intervention Analysis","Relationship Between Immune Profile and Respiratory Parameters in Down Syndrome Children With Acute Pneumonia: Pre-Intervention Analysis","Inclusion Criteria:\n\n* Down Syndrome with acute bronchopneumonia\n* sufficient cognitive ability\n\nExclusion Criteria:\n\n* severe congenital heart defects\n* primary immunodeficiencies","1 Year","6 Years",{"count":78,"type":22},"OBSERVATIONAL","Baseline serum IgG, IgA, IgM (nephelometry), total WBC count (automated analyzer), RR (manual count), and SaO2 (pulse oximetry) were measured. Pearson or Spearman correlations were used to assess relationships between immune and respiratory variables, and with age",[159],"Down Syndrome",[161],"Down Syndrome, pneumonia, immune, oxygen saturation","2026-01-16",{"date":164,"type":36},"2026-01-26",{"date":166,"type":36},"2025-07-01",{"date":168,"type":22},"2026-01-30",{"name":42,"class":43},2,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100615710","phase-3-probiotics-against-erythropoietin-resistance-in-chronic-kidney-disease-patients-100615710","NCT07296146","Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.","Effect of Probiotic Supplementation on Resistant Anaemia to Erythropoietin in Chronic Kidney Disease Patients.","Inclusion Criteria:\n\n* Adult patients with end stage renal disease for more than 3 months on regular hemodialysis (GFR less than 15 ml\u002Fmin\u002Fm2\n* Receiving stable doses of erythropoietin therapy\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Recent probiotic, antibiotic, or immunosuppressive therapy\n* Microcytic hypochromic anemia.\n* Patients with hyperparathyroidism\n* Recent or planned kidney transplantation Gastrointestinal disorders (active IBD, cancer)\n* Pregnancy or lactation\n* Severe comorbidities (e.g., active infection, malignancies)\n* Cognitive or physical inability to comply with protocol",{"count":179,"type":22},80,[105],"The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are:\n\nCan probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients.\n\nParticipants will:\n\nTake Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms",[183,28,184],"Anaemia","Regular Hemodialysis",[186,187,188,189],"Probiotic","erythropoietin","resistant anaemia","chronic kidney disease patients","2025-12-08",{"date":192,"type":36},"2025-12-22",{"date":194,"type":22},"2025-12-15",{"date":196,"type":22},"2026-05-15",{"name":42,"class":43},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":44},"100613928","phase-4-metformin-in-preventing-secondary-gliosis-following-acute-thoraco-lumbar-spinal-cord-injury-100613928","NCT07272967","Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury","Safety and Efficacy of Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury: A Randomized, Double-Blinded, Placebo-Controlled Study.","Inclusion Criteria:\n\n* Adults aged 18-65 years, who had acute, non-penetrating thoraco-lumbar SCI (T1-conus medullaris), with new neurological deficits.\n* Injury occurred within the past 24 hours before enrollment.\n* American Spinal Injury Association (ASIA) Impairment Scale grade B-D.\n* Able to undergo MRI of the spine.\n* Informed consent provided by patient or legal representative.\n\nExclusion Criteria:\n\n* Major spinal transaction or cervical spinal cord injury.\n* Prior spinal surgery or pre-existing spinal pathology (e.g., kyphosis, tumors).\n* Concomitant severe traumatic brain injury (Glasgow Coma Scale \\\u003C 13) or other CNS injury that would confound neurological assessment.\n* Known diabetes mellitus (type 1 or 2) or current use of metformin.\n* Penetrating spinal injury (e.g. gunshot, stab wound).\n* Implanted metallic devices or conditions precluding MRI.\n* Pregnancy or breastfeeding.\n* Severe comorbidities (e.g. end-stage liver disease, renal failure with eGFR\\\u003C30 mL\u002Fmin).\n* Known allergy to metformin.\n* Uncontrolled infection or sepsis at presentation.",{"count":206,"type":22},34,[208],"PHASE4","Background:\n\nSpinal cord injury (SCI) is a major global health problem, with thoraco-lumbar injuries often leading to paraplegia and incomplete neurological recovery. The glial scar, resulting from astrocyte activation at the injury site, constitutes a major barrier to axon regeneration. Given the limitations of current treatments, there is an urgent need for new interventions to improve outcomes. Metformin, a common drug for diabetes, shows promising potential as a neuroprotective agent in preclinical SCI models, where it improves motor function and reduces pain and glial scar formation. Its safety in acute neurological injury has also been supported in a recent human trial for severe traumatic brain injury.\n\nObjective:\n\nTo test the safety and efficacy of metformin in acute thoraco-lumbar SCI, focusing on neurological and functional outcomes as well as DTI metrics of spinal cord integrity.\n\nMethods. Study Design. Randomized, double-blinded, placebo-controlled study.\n\nPopulation:\n\nParticipants that will be admitted during the time of the study to Neurosurgery department at Menoufia University hospitals at Menoufia University.\n\nSetting:\n\nNeurosurgery department at Menoufia University hospitals at Menoufia University.\n\nKeywords:\n\nMetformin, spinal cord injury, gliosis, randomized controlled trial, neuroprotection",[211],"Spinal Cord Injury (SCI)",[213,214,215,216,217],"Metformin","spinal cord injury,","gliosis",", randomized controlled trial","neuroprotection","2025-11-26",{"date":220,"type":36},"2025-12-09",{"date":222,"type":22},"2026-01-01",{"date":138,"type":22},{"name":42,"class":43},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":251,"locationsCount":44},"100606837","phase-4-empagliflozin-versus-statins-in-non-alcoholic-fatty-liver-disease-100606837","NCT07180745","Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease","Assessment of Efficacy of Empagliflozin Versus Statins in Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis","Inclusion Criteria:\n\n* Adult\n* Obese\n* Hyperlipidemic\n* Diabetic patients\n* Diagnosed with non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis\n\nExclusion Criteria:\n\n* Pregnant women\n* Breast feeding women\n* Diabetic patients with ketoacidosis\n* Hyperlipidemic patients with cardiovascular dysfunction\n* Patients with NAFLD or NASH induced hepatocellular carcinoma\n* Hyperlipidemic obese diabetic patients diagnosed with NAFLD or NASH who will refuse to sign the informed consent",{"count":233,"type":22},400,[208],"The goal of this clinical trial is to assess the efficacy of Empagliflozin versus Statins as monotherapy and polytherapy in non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis.\n\nDoes drug ABC Empagliflozin versus Statins as monotherapy and polytherapy improve the controlled attenuation parameter (CAP), the liver stiffness measurement (LSM), the proportion of patients with at least one point improvement or one-stage reduction in the histological scores with respect to hepatic steatosis, hepatocellular ballooning, lobular inflammation, and fibrosis after treatment?\n\nWhat medical problems do participants have when taking Empagliflozin versus Statins as monotherapy and polytherapy?\n\nParticipants will:\n\n* Take Empagliflozin alone or Empagliflozin plus statins or Pioglitazone plus Statins or Pioglitazone alone as standard therapy every day for 3 months\n* Be directed to complete history taking. FibroScan®, abdominal ultrasound and laboratory tests of ALT, AST, ALP, platelets count, Triglycerides, Cholesterol, LDL, HDL, serum insulin and insulin resistance will be conducted at baseline and after the drug administration for 3 months.\n* Keep a diary of recording any side effects they use a rescue inhaler",[237,238],"Non-alcoholic Fatty Liver Disease NAFLD","Non-alcoholic Steatohepatitis NASH",[240,241,242,243,244],"Empagliflozin","Statin","Pioglitazone","NAFLD","NASH","2025-09-16",{"date":247,"type":36},"2025-09-18",{"date":249,"type":22},"2025-11-01",{"date":142,"type":22},{"name":42,"class":43},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":258,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":44},"100561392","intelligibility-and-acoustic-speech-performance-of-cadcam-milled-titanium-partial-dentures-100561392","NCT06589570","Intelligibility and Acoustic Speech Performance of CAD\u002FCAM Milled Titanium Partial Dentures","Inclusion Criteria:\n\n* Patients with Class IV Kennedy Classification partial edentulism.\n* Sufficient occluso-gingival height of its clinical crown\n* Full opposing arch or restored with acceptable restoration\n* Edentulous ridge covered by healthy firm muco-periosteum\n* The abutment teeth had apparently good periodontal condition\n* Adequate inter-arch space\n* All patients were apparently in good general health\n* Only patients who can be easily motivated to achieve and maintain good oral hygiene were selected\n\nExclusion Criteria:\n\n* without abnormal bony irregularity or sever lingual undercut\n* with no signs of mobility or inflammation with no tissue undercut\n* Patients with shallow floor of the mouth, prominent lingual tori, bony undercuts and lingual inclined teeth were all excluded\n* no tempro-mandibular joint disorders\n* free from systemic diseases as diabetes mellitus",true,{"count":260,"type":22},12,[25],"Partial dentures play a crucial role in restoring oral function and aesthetics for patients with missing teeth. Traditionally, these prostheses have been fabricated using materials such as acrylic resin or cobalt-chromium alloys. However, advancements in digital dentistry have introduced new materials and manufacturing techniques, including computer-aided design and computer-aided manufacturing (CAD\u002FCAM) milled titanium. While titanium offers advantages such as biocompatibility, lightweight properties, and corrosion resistance, its impact on speech performance remains understudied.",[264,265,266],"Speech","Denture, Partial, Removable","CAD-CAM","2025-09-01",{"date":269,"type":36},"2025-09-03",{"date":271,"type":36},"2024-09-09",{"date":273,"type":22},"2025-12-06",{"name":42,"class":43},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":44},"100600799","phase-4-efficacy-and-safety-of-adapalene-gel-and-hyaluronic-acid-versus-adapalene-gel-alone-in-mild-to-moderate-acne-vulgaris-100600799","NCT07102186","Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris","Comparing the Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris: An Open-label Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients with mild to moderate acne vulgaris who have not used topical retinoids or systemic acne treatments within the past 3 months will be included.\n\nExclusion Criteria:\n\n* patients with severe acne, nodulocystic acne, secondary infections, known hypersensitivity to adapalene or hyaluronic acid, pregnant, or lactating individuals.",{"count":283,"type":22},120,[208],"Acne vulgaris affects around 85% of adolescents and young adults. Adapalene, a topical retinoid, is a common treatment but often causes irritation, leading to poor adherence. Hyaluronic acid (HA), known for its hydrating and anti-inflammatory properties, may help reduce these side effects.\n\nThis prospective, open-label, randomized controlled trial compares adapalene 0.1% gel combined with HA serum versus adapalene alone over 8 weeks in patients with mild to moderate acne. Key outcomes include acne lesion reduction, incidence and severity of side effects (erythema, dryness, scaling, stinging\u002Fburning, pruritus), and skin hydration assessed through the skin turgor test. Acne severity will be measured using the Acne Severity Index (ASI) and Investigator's Global Assessment (IGA) scale.\n\nThe study anticipates better efficacy, reduced irritation, and improved skin hydration with the combination therapy. Ethical approval was obtained, and informed consent will be secured from all participants.",[287],"Acne Vulgaris",[289,290,291,292],"acne vulgaris","adapalene","Hyaluronic acid","Topical Retinoids","2025-07-28",{"date":295,"type":36},"2025-08-03",{"date":297,"type":36},"2025-07-21",{"date":299,"type":22},"2025-10-21",{"name":42,"class":43},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":258,"sex":99,"minAge":101,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":44},"100575984","pilates-mat-exercises-training-on-functional-performance-in-middle-age-obese-women-100575984","NCT06779383","Pilates Mat Exercises Training on Functional Performance in Middle Age Obese Women","Effect of Pilates Mat Exercises Training on Functional Performance in Middle Age Obese Women: Randomized Controlled Trial","Inclusion Criteria:\n\n* women\n\n  * BMI between 30 to 34.9 kg\u002Fm2\n  * Age will range from 45-55 years old.\n\n    1. Exclusion criteria\n\nExclusion Criteria:\n\n* Cardiac diseases\n\n  * Liver diseases\n  * Hypertension\n  * Musculoskeletal disease","55 Years",{"count":21,"type":22},[25],"• Aim of the study: This study will aim to investigate the effects of a 12-week Pilates-mat exercise program on the functional performance in middle age obese women.\n\nMaterials and Methods:\n\nsixty obese women patients (ages 45-55 years old) with a body mass index (BMI) 30 -34.9 kg\u002Fm2.Women will be randomly assigned into experimental group(Pilates) or control group, (3 times\u002Fweek, 60 min\u002Fsession) their age from 45 to 55 yrs. The Pilates exercises were performed on mats. The functional performance on one-leg stance (OLS), five-times-sit-to-stand (STS) and 6-min walk (6 MW) tests was evaluated before and after the 12-week Pilates training or control follow-up period.",[313],"Obese","2025-01-12",{"date":316,"type":36},"2025-01-16",{"date":318,"type":22},"2025-01-20",{"date":320,"type":22},"2025-05-29",{"name":42,"class":43},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":258,"sex":17,"minAge":308,"maxAge":53,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":44},"100561483","evaluation-of-the-effect-of-osseodensefication-technique-versus-conventional-implant-drilling-technique-in-implant-supported-mandibular-overdenture-100561483","NCT06590753","Evaluation of the Effect of Osseodensefication Technique Versus Conventional Implant Drilling Technique in Implant Supported Mandibular Overdenture","Clinical and Radiographic Evaluation of the Effect of Osseodensefication Technique Versus Conventional Implant Drilling Technique on Supporting Structure in Implant Supported Mandibular Overdenture","Inclusion Criteria:\n\n* All patients will have edentulous.\n* Patient's age ranges from 55-65 years.\n* All patients should be free from any systemic disease such as bone diseases or debilitating diseases.\n* Patient's residual ridge should be covered with firm mucosa free from any signs of inflammation, ulceration, or flabby tissue.\n* Patients should have good oral hygiene.\n\nExclusion Criteria:\n\n* Uncooperative patients will be excluded .\n* Patient with parafunctional habits (bruxism, clenching)\n* Patient with xerostomia or excessive salivation.\n* Patient with TMJ disorder.",{"count":330,"type":22},10,[25],"The present study will be performed to : evaluate the effect of two implant placement systems )conventional method and osseodensification method) radiographically on bone density and bone height surrounding the implant by using CBCT and clinically by probing depth and gingival index.",[334],"Implant Site Reaction",[336,337,338],"implant","Bone density","Bone height","2024-09-10",{"date":341,"type":36},"2024-09-19",{"date":343,"type":36},"2022-12-01",{"date":345,"type":22},"2025-01-01",{"name":42,"class":43},""]